Phenotype of BTK‐lacking Myeloid Cells During Prolonged COVID‐19 and Upon Convalescent Plasma

XLA patient with 7-month course of COVID-19 with persistent plasma SARS-CoV-2 load revealed a sustained non-inflammatory profile of myeloid cells in association with contained severity of disease, arguing in favor of the use of BTK inhibitors in SARS-COV-2 infection.